Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

C-Ray Therapeutics Partners with SHINE Technologies – Lu-177 Supply Agreement Targets China Radiopharmaceutical Market

Fineline Cube Mar 27, 2026
Company Deals

GSK Partners with SPH Keyuan Trade to Relaunch Engerix B – Hepatitis B Vaccine Targets China’s Adult Self-Paid Market

Fineline Cube Mar 26, 2026
Company Deals

MSD to Acquire Terns Pharmaceuticals for $6.7 Billion – TERN-701 BCR::ABL1 Inhibitor Targets Chronic Myeloid Leukemia

Fineline Cube Mar 26, 2026
Company Deals

Daiichi Sankyo Partners with Tempus AI – Foundation Models Target ADC Biomarker Discovery and Patient Stratification

Fineline Cube Mar 26, 2026
Company Deals

Thermo Fisher Partners with SHL Medical – Autoinjector Manufacturing Expansion Targets U.S. Drug-Device Combination Market

Fineline Cube Mar 26, 2026
Policy / Regulatory

China State Council Mandates Long-Term Care Insurance System – 0.3% Contribution Rate Targets Severe Disability Coverage Within Three Years

Fineline Cube Mar 26, 2026
Company Drug

Novo Nordisk’s Awiqli Wins FDA Approval – World’s First Once-Weekly Basal Insulin for Type 2 Diabetes

Fineline Cube Mar 27, 2026
Company Drug

Hengrui Pharma’s HRS9531 Wins NMPA Approval for Cardiovascular Outcomes Trial – Dual GIPR/GLP-1R Agonist Targets MACE Reduction

Fineline Cube Mar 27, 2026
Company Medical Device

Acotec Scientific Holdings Receives NMPA Approvals for YAN and P-Conic Balloon

Fineline Cube Dec 29, 2022

China-based Acotec Scientific Holdings Ltd (HKG: 6669) has announced receiving market approvals from the National...

Company Drug

CanSino Biologics Updates Data from COVID-19 Vaccine Clinical Studies

Fineline Cube Dec 29, 2022

China-based CanSino Biologics (HKG: 6185) has provided data updates from three clinical studies for its...

Company Deals

Fortune Care Raises Over RMB 100 Million in Series C+ Financing Round

Fineline Cube Dec 29, 2022

China-based household healthcare and nursing brand Fortune Care reportedly raised over RMB 100 million (USD...

Company Deals

Guangzhou Mygene Raises ‘Hundreds of Millions’ in Series C Financing Led by Efund Capital

Fineline Cube Dec 29, 2022

China-based molecular diagnostic product developer Guangzhou Mygene Medical Technology Co., Ltd reportedly raised “hundreds of...

Company

WuXi Biologics Receives First GMP Certificate from Ireland HPRA

Fineline Cube Dec 28, 2022

China-based Contract Research, Development, and Manufacturing Organization (CRDMO) WuXi Biologics (HKG: 2269) has announced receiving...

R&D

CARsgen Develops New CAR-T Technique to Enhance Anti-Tumor Activity

Fineline Cube Dec 28, 2022

China-based chimeric antigen receptor (CAR)-T cell specialist CARsgen Therapeutics Holdings Ltd (HKG: 2171) has announced...

Company Drug

SciClone Pharmaceuticals’ Vaborem IND Filing Accepted by NMPA

Fineline Cube Dec 28, 2022

SciClone Pharmaceuticals Inc (HKG: 6600) has announced that an Investigational New Drug (IND) filing for...

Company Drug

Luye Pharma’s Paliperidone Palmitate Accepted for NMPA Review

Fineline Cube Dec 28, 2022

China-based Luye Pharma Group (HKG: 2186) has announced that the market filing for its paliperidone...

Policy / Regulatory

China Downgrades COVID-19 from Class A to Class B Infectious Disease

Fineline Cube Dec 28, 2022

The National Health Commission (NHC) has issued a notice downgrading COVID-19 from a Class A...

Company Deals

Carrier Biomed Raises ‘Tens of Millions’ in Series A+ Financing Round

Fineline Cube Dec 28, 2022

Carrier Biomed (Soohow) Co., Ltd, an exosome technology developer based in Suzhou, has reportedly raised...

Company

Everest Medicines Launches First Phase of Global mRNA Vaccine Manufacturing Site

Fineline Cube Dec 28, 2022

China-based Everest Medicines (HKG: 1952) has announced the initiation of the operation of the first...

Company Drug

InnoCare Pharma Receives Hong Kong Approval for Tafasitamab in DLBCL

Fineline Cube Dec 28, 2022

China-based biopharma InnoCare Pharma (HKG: 9969, SHA: 688428) has announced receiving market approval from the...

Company Deals

LeadArt Biotechnologies Raises USD 6 Million in Pre-Series A Round

Fineline Cube Dec 28, 2022

LeadArt Biotechnologies Inc., a chemical proteomics specialist based in Ningbo, has reportedly raised close to...

Company Drug

Simcere Receives NMPA Clearance for SIM0237 Clinical Study

Fineline Cube Dec 28, 2022

China-based Simcere Pharmaceutical Group (HKG: 2096) has announced receiving clearance from the National Medical Products...

Company Drug

CStone Pharmaceuticals Publishes Ayvakit Study Results on Oncologist Website

Fineline Cube Dec 28, 2022

China-based CStone Pharmaceuticals (HKG: 2616) has published the results of the China-based bridging NAVIGATOR study...

Company Deals

Biosion Completes Series B Financing Round Led by Guangfa Xinde Investment

Fineline Cube Dec 28, 2022

Biosion, a global, clinical-stage biotech committed to developing antibody-based therapies targeting immune and oncologic diseases,...

Company Medical Device

BGI Genomics Receives ANVISA Approval for Colorectal Cancer Detection Kit

Fineline Cube Dec 28, 2022

China-based genomics giant BGI Genomics Co., Ltd (SHE: 300676) has reported receiving product approval from...

Company Deals

InflaRx and Staidson Amend Deal to Advance Vilobelimab Regulatory Filing in China

Fineline Cube Dec 28, 2022

Germany-based biopharma InflaRx N.V. (Nasdaq: IFRX) has revealed an amendment to its underlying deal with...

Company Drug

Elpiscience Receives IND Approval for ES014 in China

Fineline Cube Dec 27, 2022

Shanghai-based Elpiscience Biopharmaceuticals Inc. has announced receiving Investigational New Drug (IND) approval in China to...

Company Deals

Ablaze Pharma and Yonghe Partner for Targeted Radiotherapy Development

Fineline Cube Dec 27, 2022

China-based Ablaze Pharma and Yonghe Pharmaceutical have struck a partnership agreement for the research and...

Posts pagination

1 … 557 558 559 … 642

Recent updates

  • C-Ray Therapeutics Partners with SHINE Technologies – Lu-177 Supply Agreement Targets China Radiopharmaceutical Market
  • Novo Nordisk’s Awiqli Wins FDA Approval – World’s First Once-Weekly Basal Insulin for Type 2 Diabetes
  • Hengrui Pharma’s HRS9531 Wins NMPA Approval for Cardiovascular Outcomes Trial – Dual GIPR/GLP-1R Agonist Targets MACE Reduction
  • CStone Pharma 2025 Revenue RMB 269.6M Down 34% – NRDL Price Adjustment Hits Pralsetinib, Licensing Fees Decline
  • Chengdu Kanghong’s KHN922 Wins NMPA Approval – Dual-Payload HER3 ADC Targets Advanced Solid Tumors with Anti-Resistance Mechanism
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

C-Ray Therapeutics Partners with SHINE Technologies – Lu-177 Supply Agreement Targets China Radiopharmaceutical Market

Company Drug

Novo Nordisk’s Awiqli Wins FDA Approval – World’s First Once-Weekly Basal Insulin for Type 2 Diabetes

Company Drug

Hengrui Pharma’s HRS9531 Wins NMPA Approval for Cardiovascular Outcomes Trial – Dual GIPR/GLP-1R Agonist Targets MACE Reduction

Company

CStone Pharma 2025 Revenue RMB 269.6M Down 34% – NRDL Price Adjustment Hits Pralsetinib, Licensing Fees Decline

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.